Tandem Diabetes Q1 sales rise 5% to $247.2 million; net loss narrows, guidance reaffirmed
Tandem Diabetes Care reported first quarter 2026 sales of $247.2 million, up 5% from a year earlier, with gross margin rising to 55% from 51%. The company narrowed its net loss to $20.4 million, or $0.30 per share, from $130.6 million, or $1.97 per share, in the prior-year quarter, which included a $75.2 million acquired R&D charge. It reaffirmed its full-year 2026 financial guidance, including sales of $1.065 billion to $1.085 billion.
Key points
- Worldwide sales rose 5% to $247.2 million; U.S. sales rose 7% to $160.8 million and international sales rose 3% to $86.4 million
- Net loss was $20.4 million, or $0.30 per share, versus a net loss of $130.6 million, or $1.97 per share, in Q1 2025
- Gross margin was 55%, compared with 51% a year earlier; adjusted EBITDA was $2.7 million, or 1% of sales
- Company reaffirmed 2026 guidance for sales of approximately $1.065 billion to $1.085 billion
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.